{{SignSymptom infobox
 | Name           = Microalbuminuria
 | Image          =
 | Caption        =
 | DiseasesDB     =
 | ICD10          =
 | ICD9           = {{ICD9|791.0}}
 | ICDO           =
 | OMIM           =
 | MedlinePlus    = 003591
 | eMedicineSubj  =
 | eMedicineTopic =
 | MeshID         = 
}}
'''Microalbuminuria''' (Urine albumin) occurs when the kidney leaks small amounts of [[human serum albumin|albumin]] into the urine, in other words,  when there is an abnormally high [[Vascular permeability|permeability]] for albumin in the [[renal glomerulus]].

==Diagnosis==
The level of albumin [[protein]] produced by microalbuminuria can be detected by special albumin-specific urine [[dipstick]]s. A [[microalbumin urine test]] determines the presence of the albumin in urine. In a properly functioning body, albumin is not normally present in urine because it is retained in the bloodstream by the kidneys.

Microalbuminuria can be diagnosed from a 24-hour urine collection (between 30–300&nbsp;mg/24 hours) or, more commonly, from elevated concentrations in a spot sample (30 to 300&nbsp;mg/L).  Both must be measured on at least two of three measurements over a two- to three-month period.<ref>{{cite web |url=http://meteor.aihw.gov.au/content/index.phtml/itemId/270336 |title=Person—microalbumin level (measured), total micrograms per minute N[NNN].N |accessdate=2007-07-05 |work=}}</ref> 

An albumin level above the upper limit values is called "macroalbuminuria", or sometimes just [[albuminuria]]. Sometimes, the upper limit value is given as one less (such as 300 being given as 299) to mark that the higher value (here 300) is defined as macroalbuminuria.<ref name=Lee2009/>

To compensate for variations in urine concentration in spot-check samples, it is helpful to compare the amount of albumin in the sample against its concentration of [[creatinine]]. This is termed the '''albumin/creatinine ratio''' ('''ACR''')<ref>{{cite journal | pmid = 10333950 | volume=22 | issue=2 | title=Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration | year=1999 | month=February | author=Bakker AJ | journal=Diabetes Care | pages=307–13}}</ref> and microalbuminuria is defined as ACR ≥3.5&nbsp;mg/mmol (female) or ≥2.5&nbsp;mg/mmol(male),<ref>{{cite web |title=Proteinuria |date=December 15, 2005 |url=http://www.renal.org/eGFR/proteinuria.html |publisher= UK Renal Association}}</ref> or, with both substances measured by mass, as an ACR between 30 and 300&nbsp;µg albumin/mg creatinine.<ref>[http://www.clinlabnavigator.com/index.php?option=com_content&view=article&id=412:microalbumin&catid=35:test-interpretations clinlabnavigator.com > Test Interpretations] Last Updated on Saturday, 19 June 2010</ref>
For the diagnosis of microalbuminuria, care must be taken when collecting sample for the urine ACR. An early morning sample is preferred. The patient should refrain from heavy exercises 24 hours before the test. A repeat test should be done 3 to 6 months after the first positive test for microalbuminuria. Lastly, the test is inaccurate in a person with too much or too little muscle mass. This is due to the variation in creatinine level which is produced by the muscle.<ref>[http://www.treatmentandsymptoms.com/renal-nephrology/microalbuminuria-in-type-2-diabetes-mellitus/ Microalbuminura in diabetes]</ref>
{|class="wikitable" align="center"
|+ Definitions of microalbuminuria
|-
!  !! Individual !! Lower limit !! Upper limit !! Unit
|-
! 24h urine collection
|  || 30<ref name=Lee2009>[http://books.google.com/books?id=AUSIRcV_as0C&pg=PA291 Page 291] in: {{Cite book|isbn=978-1-58528-180-0|postscript=<!-- Bot inserted parameter. Either remove it; or change its value to "." for the cite to end in a ".", as necessary. -->{{inconsistent citations}}}}</ref> || 300<ref name=Lee2009/> || mg/24h ([[milligram]] albumin per 24 hours)
|-
! Short-time urine collection
|  || 20<ref name=Lee2009/> || 200<ref name=Lee2009/> || µg/min ([[microgram]] albumin per minute)
|-
! Spot urine albumin sample
|  || 30<ref name=aihw>[http://meteor.aihw.gov.au/content/index.phtml/itemId/270339 Person—microalbumin level (measured)] at Australian Institute of Health and Welfare. 01/03/2005</ref> || 300<ref name=aihw/> || mg/l (milligram albumin per [[litre]] of urine) or <br> µg/g (microgram albumin per gram of urine)
|-
!rowspan=4| Spot urine albumin/creatinine ratio
|rowspan=2| Women || 3.5<ref name=Justesen2006>[http://care.diabetesjournals.org/content/29/4/924.full] {{cite pmid|16567839}}</ref> || 25<ref name=Justesen2006/> or 35<ref name=Justesen2006/> || mg/mmol (milligram albumin per [[millimole]] creatinine) 
|-
| 30<ref name=Justesen2006/> || 400<ref name=Justesen2006/> || μg/mg (microgram albumin per milligram creatinine)
|-
|rowspan=2| Men || 2.5<ref name=Justesen2006/> or 3.5<ref name=Justesen2006/> || 25<ref name=Justesen2006/> or 35<ref name=Justesen2006/> || mg/mmol 
|-
| 30<ref name=Justesen2006/> || 300<ref name=Justesen2006/> || μg/mg
|}

==Significance==
* an indicator of subclinical cardiovascular disease
* marker of vascular [[endothelial dysfunction]]
* an important prognostic marker for kidney disease
** in [[diabetes mellitus]]
** in [[hypertension]]
** in [[Post-streptococcal glomerulonephritis]]
* increasing microalbuminuria during the first 48 hours after admission to an [[intensive care unit]] predicts elevated risk for acute [[respiratory failure]], [[multiple organ failure]], and overall mortality
* a risk factor for venous thromboembolism <ref>{{cite journal|pmid=19417196|year=2009|last1=Mahmoodi|first1=BK|last2=Gansevoort|first2=RT|last3=Veeger|first3=NJ|last4=Matthews|first4=AG|last5=Navis|first5=G|last6=Hillege|first6=HL|last7=Van Der Meer|first7=J|author8=Prevention of Renal Vascular End-stage Disease (PREVEND) Study Group|title=Microalbuminuria and risk of venous thromboembolism|volume=301|issue=17|pages=1790–7|doi=10.1001/jama.2009.565|journal=JAMA: the Journal of the American Medical Association}}</ref>

==See also==
* [[Albuminuria]]

==References==
* {{cite journal |author=Abid O, Sun Q, Sugimoto K, Mercan D, Vincent JL |title=Predictive value of microalbuminuria in medical ICU patients: results of a pilot study |journal=Chest |volume=120 |issue=6 |pages=1984–8 |year=2001 |pmid=11742932 |doi=10.1378/chest.120.6.1984}}
* {{cite journal |author=Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD |title=Glomerular permselectivity in early stages of overt diabetic nephropathy |journal=Kidney Int. |volume=58 |issue=5 |pages=2129–37 |year=2000 |pmid=11044234 |doi=10.1111/j.1523-1755.2000.00386.x}}
* {{cite journal |author=Heart Outcomes Prevention Evaluation Study Investigators  |title=Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy |journal=Lancet |volume=355 |issue=9200 |pages=253–9 |year=2000 |pmid=10675071 |doi=10.1016/S0140-6736(99)12323-7}}
* {{cite journal |author=Lemley KV |title=Evolution of incipient nephropathy in type 2 diabetes mellitus |journal=Kidney Int. |volume=58 |issue=3 |pages=1228–37 |year=2000 |pmid=10972685 |doi=10.1046/j.1523-1755.2000.00223.x |author-separator=, |author2=Abdullah I |author3=Myers BD |display-authors=3 |last4=Meyer |first4=Timothy W |last5=Blouch |first5=Kristina |last6=Smith |first6=William E |last7=Bennett |first7=Peter H |last8=Nelson |first8=Robert G}}
* {{cite journal |author=Lièvre M |title=The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group |journal=Controlled clinical trials |volume=21 |issue=4 |pages=383–96 |year=2000 |pmid=10913814 |doi=10.1016/S0197-2456(00)00060-X |author-separator=, |author2=Marre M |author3=Chatellier G |display-authors=3 |last4=Plouin |first4=P |last5=Réglier |first5=J |last6=Richardson |first6=L |last7=Bugnard |first7=F |last8=Vasmant |first8=D}}
* {{cite journal |author=Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P |title=The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes |journal=N. Engl. J. Med. |volume=345 |issue=12 |pages=870–8 |year=2001 |pmid=11565519 |doi=10.1056/NEJMoa011489}}

==Footnotes==
{{reflist}}

==External links==
* [http://www.pace-med-apps.com/uAlbCalc.htm Online Microalbumin Urine Calculator]
* [http://www.roadmapstudy.org/ first-ever large-scale clinical trial to evaluate whether an ARB can prevent the initial development of Microalbuminuria]

{{Abnormal clinical and laboratory findings for urine}}

[[Category:Abnormal clinical and laboratory findings for urine]]